Addrenex Pharmaceuticals Files SNDA Submission For Clonicel To Treat ADHD

Main Category: ADHD
Article Date: 04 Oct 2009 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD). The submission is based on the successful completion of Phase III clinical trials demonstrating statistical significance when Clonicel was used to treat ADHD in children and adolescents.

"The sNDA filing for Clonicel is an important milestone for physicians and the millions of patients and their families seeking a non-stimulant alternative for the treatment of ADHD," said Moise Khayrallah, PhD, Chief Executive Officer of Addrenex Pharmaceuticals. "For Addrenex, this filing is another exciting accomplishment in our company's brief history, further validating our drug development model in bringing new drugs to market to fill unmet needs."

Clonicel is the company's lead compound in a pipeline of products targeting conditions arising from an overactive adrenergic system, the body's control center for regulating stress and a host of other physiologic functions. In less than three years since the specialty pharmaceutical company's founding, Durham-based Addrenex has developed a promising portfolio of four products in clinical trials and over 400 compounds available for future development to treat hypertension, ADHD, narcolepsy, procedural sedation, insomnia, menopausal flushing and dermatologic indications.

The North American rights to market Clonicel are licensed to Atlanta based specialty pharmaceutical company Sciele Pharma. Ed Schutter, President and Chief Operating Officer of Sciele Pharma, said, "We are pleased that Addrenex has filed the sNDA with the FDA. Clonicel is an important product in our pediatric pipeline, and we are excited about the potential benefit that Clonicel may provide to children and adolescents who have ADHD."

About Sciele Pharma, Inc.

Sciele Pharma, Inc., a Shionogi Company, is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on the therapeutic areas of Cardiovascular, Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular and Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma and attention deficit and hyperactivity disorder (ADHD). Founded in 1992 and headquartered in Atlanta, Georgia, Sciele employs approximately 1,000 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity, and Teamwork. For more information on Sciele, please visit http://www.sciele.com.

Source
Addrenex Pharmaceuticals